| Epoch Biodesign–Extantia Capital: investment, 202503 financing round Series A totalling $18.3m incl lead investor Extantia Capital |
2025-03-05 |
| Epoch Biodesign–SEVERAL: investment, 202503 financing round Series A $18.3m led by Extantia Capital |
2025-03-05 |
| Trimtech Therapeutics–SEVERAL: investment, 202503 seed financing round £25m led by Cambridge Innovationn Capital + DDF |
2025-03-05 |
| Callio Therapeutics–Hummingbird Bioscience: antibody-drug conjugates, 202503– license excl ww ADC technology in oncology + related IP + pipeline |
2025-03-03 |
| Callio Therapeutics–SEVERAL: investment, 202503 financing round Series A $187m led by founding investor Frazier Life Sciences |
2025-03-03 |
| Fuse Vectors–SEVERAL: investment, 202502 pre-seed financing round €5m led by HCVC |
2025-02-25 |
| VeroVaccines–SEVERAL: investment, 202502 financing round Series €1.6m from existing investors + founders |
2025-02-25 |
| Bluebird Bio–Carlyle: investment, 202502– acquisition of Bluebird Bio by funds managed by Carlyle + SK Capital Partners + delisting |
2025-02-21 |
| Bluebird Bio–SK Capital: investment, 202502– acquisition of Bluebird Bio by funds managed by Carlyle + SK Capital Partners + delisting |
2025-02-21 |
| EG427–SEVERAL: investment, 202502 financing round Series B €27m co-led by Andera Partners + Bpifrance InnoBio funds |
2025-02-20 |
| FibroGen–AstraZeneca: investment, 202502 acquisition $160m (incl acquired net cash of $75m) of FibroGen China by AZ incl rights to roxadustat in China |
2025-02-20 |
| Atai Life Sciences–Angermayer Group: investment, 202502 public offering totalling $63.25m incl $22.75m from Apeiron raising share from 19.9% to 22.3% |
2025-02-19 |
| Atai Life Sciences–SEVERAL: investment, 202502 public offering $55m+$8.25m with 26.19m+3.93m common shares at $2.1/share |
2025-02-19 |
| Atrandi Biosciences–Grids Capital: investment, 202502 financing round Series A totalling $25m incl co-investor Grids Capital |
2025-02-19 |
| Atrandi Biosciences–KKH Advisors: public relations, 202502 service existent by KKH Advisors |
2025-02-19 |
| Atrandi Biosciences–Lux Capital: investment, 202502 financing round Series A totalling $25m incl lead investor Lux Capital |
2025-02-19 |
| Atrandi Biosciences–Metaplanet: investment, 202502 financing round Series A totalling $25m incl co-investor Metaplanet |
2025-02-19 |
| Atrandi Biosciences–Practica Capital: investment, 202502 financing round Series A totalling $25m incl co-investor Practica Capital |
2025-02-19 |
| Atrandi Biosciences–SEVERAL: investment, 202502 financing round Series A $25m led by Lux Capital |
2025-02-19 |
| Atrandi Biosciences–Vsquared Ventures: investment, 202502 financing round Series A totalling $25m incl co-investor Vsquared Ventures |
2025-02-19 |
| Anbio Biotechnology–SEVERAL: investment, 202502 IPO $8m net $7.44m at Nasdaq Global Market with 1.6m Class A ordinary shares at $5/share |
2025-02-18 |
| Bambusa Therapeutics–SEVERAL: investment, 202502 financing round Series A $90m led by new investor RA Capital Management |
2025-02-14 |
| Bürkert Fluidic Control Systems–Green Elephant Biotech: cell culture technology, 202502 strategic partnership incl strategic investment by Bürkert |
2025-02-13 |
| Green Elephant Biotech–Bürkert Fluidic Control Systems: investment, 202502 strategic investment by Bürkert as part of strategic partnership |
2025-02-13 |
| Latent Labs–SEVERAL: investment, 202502 financing round Series A $40m co-led by Radical Ventures + Sofinnova Partners |
2025-02-13 |
| Latent Labs–SEVERAL: investment, <202502 financing round pre-Series A? $10m incl 8VC + Kindred Capital + Pillar VC |
2025-02-13 |
| Newronika–F3F (IT): investment, 202502 financing round Series B totalling €13.6m incl existing + co-investor F3F |
2025-02-13 |
| Newronika–Indaco Venture: investment, 202502 financing round Series B totalling €13.6m incl existing + co-investor Indaco Venture Partners SGR |
2025-02-13 |
| Newronika–Innogest: investment, 202502 financing round Series B totalling €13.6m incl existing + co-investor Innogest SGR |
2025-02-13 |
| Newronika–Italy (govt): investment, 202502 financing round Series B totalling €13.6m new + lead investor ENEA Tech e Biomedical |
2025-02-13 |
| Newronika–SEVERAL: investment, 202502 financing round Series B €13.6m led by Fondazione ENEA Tech e Biomedical |
2025-02-13 |
| Newronika–TNBT Capital: investment, 202502 financing round Series B totalling €13.6m incl existing + co-investor TNBT Capital |
2025-02-13 |
| Newronika–Wille Finance: investment, 202502 financing round Series B totalling €13.6m incl existing + co-investor Wille Finance |
2025-02-13 |
| Ochre Bio–Som.X: public relations, 202502 service existent? Ochrebio listed as client at web site |
2025-02-13 |
| Oculis–SEVERAL: investment, 202502 underwritten offering $100m with 5m ordinary shares at $20/share |
2025-02-13 |
| Ori Biotech–Som.X: public relations, 202502 service existent? Oribiotech listed as client at web site |
2025-02-13 |
| Pfizer–Som.X: public relations, 202502 service existent? Pfizer listed as client at web site |
2025-02-13 |
| Stilla Technologies–Bio-Rad: investment, 202502– acquisition 100% of Stilla Technologies by Bio-Rad SIGNED |
2025-02-13 |
| Phaeosynt–Fonde Ventures: investment, 202502 seed financing round totalling €1.7m incl new investor Fonde Ventures |
2025-02-12 |
| Phaeosynt–Lower Saxony (govt): investment, 202502 seed financing round totalling €1.7m incl new investor NBank Capital Beteiligungsgesellschaft mbH |
2025-02-12 |
| Phaeosynt–OTHER: investment, 202502 seed financing round totalling €1.7m incl existing investors |
2025-02-12 |
| Phaeosynt–PERSON: investment, 202502 seed financing round totalling €1.7m incl new investor Thomas Tönnesmann |
2025-02-12 |
| Phaeosynt–PERSON: investment, 202502 seed financing round totalling €1.7m incl new investor Ulrich Gehrke |
2025-02-12 |
| Phaeosynt–PSD Bank: investment, 202502 seed financing round totalling €1.7m incl new investor PSD Braunscheig Verwaltungs-GmbH |
2025-02-12 |
| Phaeosynt–Renditei: investment, 202502 seed financing round totalling €1.7m incl new investor Renditei UG |
2025-02-12 |
| Phaeosynt–SEVERAL: investment, 202502 seed financing round €1.7m from existing + new investors |
2025-02-12 |
| Phaeosynt–TrueNorth Ventures: investment, 202502 seed financing round totalling €1.7m incl new investor TrueNorth Ventures UG |
2025-02-12 |
| Anthos Therapeutics–Novartis: investment, 2020502– acquisition $925m upfront + $2.15b milestones by Novartis from majority owner Blackstone LS et al |
2025-02-11 |
| Avelios Medical–SEVERAL: investment, 202502 financing round Series A €30m led by Sequoia Capital |
2025-02-06 |
| Avalyn Pharma–Qureight: drug development services, 202502– collab using Qureight imaging technology in multiple Avalyn clinical studies |
2025-02-05 |
| Qureight–Som.X: public relations, 202502 service existent SomX is media contact for Qureight |
2025-02-05 |
| Akribion–Bruker: investment, 202502 seed financing round totalling €8m incl co-investor Bruker Invest |
2025-02-04 |
| Akribion–Carma Fund: investment, 202502 seed financing round totalling €8m incl co-lead investor Carma Fund |
2025-02-04 |
| Akribion–Hessen (govt): investment, 202502 seed financing round totalling €8m incl co-investor Hessen Kapital I |
2025-02-04 |
| Akribion–High-Tech Gründerfonds: investment, 202502 seed financing round totalling €8m incl co-investor HTGF |
2025-02-04 |
| Akribion–Optimum Strategic Communications: public relations, 202502 service existent by Optimum |
2025-02-04 |
| Akribion–Putsch (Recaro): investment, 202502 seed financing round totalling €8m incl co-investor MP Beteiligungs-GmbH |
2025-02-04 |
| Akribion–SEVERAL: investment, 202502 seed financing round €8m led by Carma Fund + RV Invest |
2025-02-04 |
| Akribion–Vetter: investment, 202502 seed financing round totalling €8m incl co-lead investor RV Invest |
2025-02-04 |
| Knauer–Labomatic Instruments: liquid chromatography 202502– collab strategic combining HPLC offerings to customers incl sales + service |
2025-02-03 |
| Evaxion Biotech–SEVERAL: investment, 202501 public offering $10.8m with 4m ADSs each with 2 attached warrants at $2.71/ADS+warrants |
2025-01-31 |
| Quibim–SEVERAL: investment, 202501 financing round Series A $50m led by Asabys + Beunavista Equity Partners |
2025-01-28 |
| Arctic Therapeutics–SEVERAL: investment, 202501 financing round Series A €26.5m |
2025-01-22 |
| Candor Bioscience–Medix Biochemica: investment, 202501 acquisition of Candor Bioscience GmbH by Medix Biochemica |
2025-01-22 |
| 4basebio–Circio: synthetic DNA vectors, 202501– collab developm integration of circVEC system with Hermes platform + hpDNA + opDNA |
2025-01-21 |
| Zwisler Laboratorium–Cormica: investment, 202501 acquisition of Zwisler Laboratorium GmbH by Cormica |
2025-01-20 |
| Bureau Veritas–SGS: investment, 202501– confirmed merger discussion |
2025-01-15 |
| Owlstone–Aviva: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Aviva Ventures |
2025-01-15 |
| Owlstone–Gates Foundation: grant, 202404– initial $1.5m grant to develop breat-based diagnostics for developing countries from Gates Foundation |
2025-01-15 |
| Owlstone–Horizons Ventures: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Horizon Ventures |
2025-01-15 |
| Owlstone–SEVERAL: investment, 202501 financing round Series E first closing $27m led by Ventura Capital |
2025-01-15 |
| Owlstone–Ventura Capital: investment, 202501 financing round Series E first closing totalling $27m incl existing + lead investor Ventura Capital |
2025-01-15 |
| Bioptimus–Boom Capital Ventures: investment, 202501 financing round totalling $41m incl co-investor Boom Capital Ventures |
2025-01-14 |
| Bioptimus–Cathay Capital: investment, 202501 financing round totalling $41m incl existing + lead investor Cathay Innovation |
2025-01-14 |
| Bioptimus–France (govt): investment, 202501 financing round totalling $41m incl existing + co-investor Bpifrance Large Venture Fund |
2025-01-14 |
| Bioptimus–Hitachi: investment, 202501 financing round totalling $41m incl co-investor Hitachi Ventures |
2025-01-14 |
| Bioptimus–New York Life: investment, 202501 financing round totalling $41m incl co-investor Andera Partners |
2025-01-14 |
| Bioptimus–PERSON: investment, 202501 financing round totalling $41m incl angel entrepreneurs Emmanuel Cassimatis |
2025-01-14 |
| Bioptimus–PERSON: investment, 202501 financing round totalling $41m incl angel entrepreneurs Thomas Wolf |
2025-01-14 |
| Bioptimus–Pomifer Capital: investment, 202501 financing round totalling $41m incl co-investor Pomifer Capital |
2025-01-14 |
| Bioptimus–SEVERAL: investment, 202501 financing round $41m led by Cathay Innovation |
2025-01-14 |
| Bioptimus–Sofinnova: investment, 202501 financing round totalling $41m incl existing +co-investor Sofinnova Partners |
2025-01-14 |
| Bioptimus–Sunrise: investment, 202501 financing round totalling $41m incl co-investor Sunrise |
2025-01-14 |
| Ariceum Therapeutics–ITM: radiopharmaceuticals, 202501– supply €na of n.c.a.Ac-225 for Ariceum radiopharma candidates by Actineer |
2025-01-13 |
| Daiichi Sankyo–Glycotope: antibody-drug conjugates, 202501 acquisition all IPRs $132.5m for use of gatipotuzumab in ADC DS-3939 |
2025-01-13 |
| IBA Lifesciences–Cube Biotech: investment, 202501 acquisition of IBA Lifesciences by Cube Biotech backed by majority owner Archimed |
2025-01-13 |
| IDRx–GSK: investment, 202501– acquisition 100% of IDRx for $1b upfront + $150m milestones by GSK |
2025-01-13 |
| Normunity–Sanofi: investment, 202501 financing round Series B totalling $75m incl existing + co-investor Sanofi Ventures |
2025-01-13 |
| Normunity–SEVERAL: investment, 202501 financing round Series B $75m co-led by Samsara BioCapital + Enavate Sciences |
2025-01-13 |
| SpinChip Diagnostics–Mérieux: investment, 202501– acquisition of remaining 80% of SpinChip for €111m in cash by bioMérieux |
2025-01-13 |
| Windward Bio–Blue Owl Capital: investment, 202501 financing round Series A totalling $200m incl co-lead investor Blue Owl Healthcare Opportunities |
2025-01-10 |
| Windward Bio–Kelun Pharmaceutical: TSLP antibody, 202501– license ww excl China + smaller Asian markets to WIN378 from Kelun-Biotech + Harbour Biomed |
2025-01-10 |
| Windward Bio–Nan Fung: investment, 202501 financing round Series A totalling $200m incl co-investor Pivotal bioVenture Partners |
2025-01-10 |
| Windward Bio–Novo Group: investment, 202501 financing round Series A totalling $200m incl co-lead investor Novo Holdings |
2025-01-10 |
| Windward Bio–Omega Funds: investment, 202501 financing round Series A totalling $200m incl co-investor Omega Funds |
2025-01-10 |
| Windward Bio–OrbiMed: investment, 202501 financing round Series A totalling $200m incl co-lead investor OrbiMed |
2025-01-10 |
| Windward Bio–Qiming: investment, 202501 financing round Series A totalling $200m incl co-investor Qiming Venture Partners |
2025-01-10 |
| Windward Bio–Quan Capital: investment, 202501 financing round Series A totalling $200m incl co-investor Quan Capital |
2025-01-10 |
| Windward Bio–RTW Investments: investment, 202501 financing round Series A totalling $200m incl co-investor RTW Investments |
2025-01-10 |
| Windward Bio–SEVERAL: investment, 202501 financing round Series A $200m led by OrbiMed + Novo Holdings + Blue Owl Healthcare Opportunities |
2025-01-10 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
